CMS 8A8

SGD 1.71 +0.00% +0.00 Updated 17 Nov 2026, 15:46 SGT

Company profile

The business, the people and the ownership behind CMS.

Business overview

About the company

China Medical System operates healthcare-related businesses, including an integrated pharmaceutical business and a skin health business. Its research portfolio also includes drug development programmes described in its annual report.

Annual Report 2025 ↗ Reviewed 2026-10-23 · Source dated 2026-04-01. PDF p. 115

Listed security

Company & listing

Full Company Name
CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Trading Currency
SGD
Website
web.cms.net.cn
Listing
Listed on 15 July 2025 on MAINBOARD
ISIN Code
KYG211081248

Board & management

Leadership

Mr. Lam Kong

Chairman; Chief Executive; President; executive Director

Board of Directors and Chief Executive

Ms. Chen Yanling

Chief Financial Officer; Vice-president; executive Director

Board of Directors

Mr. Leung Chong Shun

independent non-executive Director

Board of Directors

Ms. Luo Laura Ying

independent non-executive Director

Board of Directors

Mr. Fung Ching Simon

independent non-executive Director

Board of Directors

Roles listed in CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025; current appointments are not independently verified.

Holdings

Ownership

Mr. Lam Kong

Interest in controlled corporation; 1,167,564,000 (L) shares; approximately 47.86% of the Company; held through Treasure Sea Limited, a company wholly owned by him (controlling shareholder)

Directors' and Chief Executive's interests in shares of the Company; long position (L); deemed/corporate interest, not nominee

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

Group structure

Main operating subsidiaries

CompanyMarketOwnership interest
Kangzhe Hunan31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Production of medicines
Tibet Kangzhe Enterprise Management Co. Ltd.31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Investment holding
Shenzhen Kangzhe31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Marketing, promotion and sale of drugs
Sino Talent31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Investment holding
Sky United31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Trading of drugs
Kangzhe Pharmaceutical Investment Co., Ltd.31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Investment holding
Tianjin Kangzhe31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Marketing, promotion and sale of drugs
Tibet Kangzhe Development31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Marketing, promotion and sale of drugs
CMS Bridging Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Investment holding
CMS Medical Venture Investment (HK) Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Investment holding
CMS International Development and Management Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 Macau; 100% indirectly held; Trading of drugs
CMS Pharma DMCC31 December 2025; 2024 also 100% indirectlyPDF p. 178 Dubai; 100% indirectly held; Trading of drugs
Shanghai Dermavon Pharmaceutical Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Marketing and promotion of drugs
Hainan Dermavon Pharmaceutical Technology Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Marketing, promotion and sale of drugs
Hainan Kangzhe Venture Capital Co. Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 178 PRC; 100% indirectly held; Investment holding
Dermavon Limited31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Trading of drugs
RXILIENT MEDICAL (HONG KONG) LIMITED31 December 2025; 2024 also 100% indirectlyPDF p. 178 Hong Kong; 100% indirectly held; Trading of drugs
Heling Medical (Guangzhou) Company Limited31 December 2025; 2024 also 60% indirectlyPDF p. 179 PRC; 60% indirectly held; Production of skincare products
Hainan Kangzhe Vision Technology Co., Ltd31 December 2025; 2024 also 100% indirectlyPDF p. 179 PRC; 100% indirectly held; Marketing, promotion and sale of drugs
CMS Vision International Management Limited31 December 2025; 2024 also 100% indirectlyPDF p. 179 Macau; 100% indirectly held; Trading of drugs
DERMAVON INTERNATIONAL BUSINESS LIMITED31 December 2025; 2024 also 100% indirectlyPDF p. 179 Macau; 100% indirectly held; Trading of drugs

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.

Senior executives

Key management

Key management

ItemValuePeriod / scopeSource
Mr. Ma Lieyi General Manager of the Operations and Management Center of the Group Senior management PDF p. 47
Mr. Jiang Qingfu General Manager of Cardio-cerebrovascular/Digestion Business (Shenzhen Kangzhe) of the Group Senior management PDF p. 47
Ms. Li Yufang General Manager of the Finance Center of the Group Senior management PDF p. 47
Mr. Fan Jie Deputy General Manager; General Manager of Off-hospital Business and Supply Chain Center of the Group Senior management PDF p. 47
Mr. Cai Ping Deputy General Manager; General Manager of the Strategic Market of the Group Senior management PDF p. 47
Mr. Huang Anjun General Manager of Dermatology Business (Dermavon) of the Group Senior management PDF p. 48
Dr. Peng Huaizheng Chief Business Officer of the Group Senior management PDF p. 48
Mr. Jiang Fei Chief Investment Officer (Greater China) of the Group Senior management PDF p. 48
Mr. James Stearns Chief Investment Officer (Europe and America) of the Group Senior management PDF p. 48
Ms. Wang Linlang General Manager of Ophthalmology Business (CMS Vision) of the Group Senior management PDF p. 48
Ms. Wu Sanyan Company Secretary; Director of the Legal Department of the Group Company Secretary PDF p. 48

Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.

Shareholding statistics

Share capital & shareholders

Share capital

ItemValuePeriod / scopeSource
At 31 December 2024 and 2025 2,439,529 '000 shares Issued and fully paid ordinary shares of US$0.005 each, at 31 December 2025 (same at 31 December 2024) · As at 2025-12-31 PDF p. 155
Authorised 20,000,000 '000 shares Authorised ordinary shares of US$0.005 each, at 1 January 2024, 31 December 2024 and 31 December 2025 · As at 2025-12-31 PDF p. 155

Treasury shares

ItemValuePeriod / scopeSource
treasury stock 19,027,000 shares Shares held as treasury stock at 31 December 2025 · As at 2025-12-31 PDF p. 156
treasury stock 23,000,000 shares Shares held as treasury stock at 31 December 2024 (comparative) · As at 2024-12-31 PDF p. 156

Free float

ItemValuePeriod / scopeSource
Sufficiency of Public Float at least 25% of the Company’s total issued share capital was held by the public in compliance with the public float requirement under the Listing Rules During the Reporting Period and as at the date of the Annual Report PDF p. 62

Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.

Related parties, people & properties

Other disclosures

Related party transactions

ItemValuePeriod / scopeSource
Tibet Pharmaceutical 1,468,071 RMB'000 Group; Associate; Promotion income; 2025 (2024: 1,395,476) PDF p. 171
ETC 16,183 RMB'000 Group; Associate; Purchase of goods; 2025 (2024: 9,337) PDF p. 171
ETC 5,505 RMB'000 Group; Associate; Promotion income; 2025 (2024: 9,110) PDF p. 171
A&B (HK) Company Limited 2,018 RMB'000 Group; Related party; Royalty expenses; 2025 (2024: 2,699) PDF p. 171
PharmaGend Global Medical Services Pte. Ltd. 9,408 RMB'000 Group; Related party; Service fee; 2025 (2024: -) PDF p. 171

Contingent liabilities

ItemValuePeriod / scopeSource
Contingent Liabilities the Group had no material contingent liabilities Group · As at 2025-12-31 PDF p. 44

Director remuneration

ItemValuePeriod / scopeSource
Total emoluments 13,895 RMB'000 All directors and chief executive total, year ended 31 December 2025 (2024: 17,244) PDF p. 120
Total emoluments 17,244 RMB'000 All directors and chief executive total, year ended 31 December 2024 PDF p. 120
Total 11 number of persons Senior management incl. Company Secretary, excluding directors, 2025; bands HK$1,500,001-HK$3,500,000 PDF p. 59

Employees

ItemValuePeriod / scopeSource
Employees 6,415 employees Group · As at 2025-12-31 PDF p. 59

Subsequent events

ItemValuePeriod / scopeSource
Exclusive distribution agreement for Lidoderm Lidocaine Cataplasms on 12 February 2026, the Group through subsidiaries of the Company entered into an exclusive distribution agreement with Teikoku Pharma USA, Inc. Group · As at 2026-02-12 PDF p. 36
Approval of Drug Clinical Trials for CMS-D017 On 3 February 2026, the NMPA has approved the Group to conduct clinical trials in healthy participants in China Group · As at 2026-02-03 PDF p. 36
Final dividend declared the Board of Directors have declared a final dividend of RMB0.1366 per ordinary share Group; year ended 31 December 2025 PDF p. 125

Outlook

ItemValuePeriod / scopeSource
Outlook The Group will continue to anchor on unmet clinical needs, deepen innovation upgrading, strengthen commercialization capabilities, advance industrial internationalization and accelerate digital intelligence-enabled operational upgrades. Chairman's Statement PDF p. 10

Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.

Source: CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 ↗

Corporate information

Registration & contacts

Incorporated In
CAYMAN ISLANDS
Incorporated On
18 Dec 2006
Email
[email protected]
Registered Office
PO Box 309
Ugland House
Grand Cayman, KY1-1104, Cayman Islands
Secretary
Wu Sanyan
Registrar / Transfer Agent
ASCENTIUM CORPORATE SERVICES PTE. LTD.
Registrar Address
36 Robinson Road, #20-01 City House, Singapore 068877
Auditors
DELOITTE TOUCHE TOHMATSU
Other Stock Exchange Listings
HONG KONG EXCHANGES AND CLEARING LTD|*SINGAPORE EXCHANGE LTD.
Country
CAYMAN ISLANDS
Security Type
stocks